Data from a clinical trial of NGX426 to be announced

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company`s orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

Mark Wallace, M.D., Professor of Clinical Anesthesiology at the Center for Pain Medicine of the University of California at San Diego ("UCSD") will present results from a proof of concept clinical trial titled, "NGX426, An Oral AMPA-Kainate Antagonist, is Effective in Human Capsaicin Induced Hyperalgesia Model." NGX426 is a prodrug of Raptor`s parenterally administered product candidate tezampanel. When given subcutaneously and intravenously tezampanel demonstrated statistically significant analgesic effect in five Phase II trials. The five trials were completed in acute migraine, nociceptive pain and neuropathic pain models.

Results and details of the study will be presented on November 20, 2009 during Dr. Wallace`s presentation.